Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis

Systemic Lupus Erythematosus

Response to ustekinumab treatment in patients with systemic lupus erythematosus is linked to suppression of serum interferon gamma levels

Arthritis Rheumatol

Cesaroni M, Seridi L, Loza MJ, Schreiter J, Sweet K, Franks C, Ma K, Orillion A, Campbell K, Gordon R, Branigan P, Lipsky P, van Vollenhoven R, Hahn BH, Tsokos GC, Chevrier M, Rose S, Baribaud F, Jordan J

doi: 10.1002/art.41547

Psoriatic Arthritis

Serum CRP, IL-17A, and IL-17F levels are responsive to ustekinumab in psoriatic arthritis: lessons from the PSUMMIT study programme

Arthritis Rheumatol.

Siebert S, Sweet K, Dasgupta B, Campbell K, McInnes IB, Loza MJ

doi: 10.1002/art.40921.

Psoriatic ArthritisRheumatoid ArthritisSpinal Disorders

Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study

Arthritis Res Ther.

Gehin JE, Goll GL, Warren DJ, Syversen SW, Sexton J, Strand EK, Kvien TK, Bolstad N, Lie E

doi: 10.1186/s13075-019-2009-5.

Psoriasis

Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis

JAMA Dermatol.

van Vugt LJ, van den Reek JMPA, Hannink G, Coenen MJH, de Jong EMGJ

doi: 10.1001/jamadermatol.

Systemic Lupus Erythematosus

Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus

Arthritis Res Ther.

Sohrabian A, Parodis I, Carlströmer-Berthén N, Frodlund M, Jönsen A, Zickert A, Sjöwall C, Bengtsson AA, Gunnarsson I, Rönnelid J

doi: 10.1186/s13075-019-2056-y.

Further Publications Dermatology

The use of psoriasis biomarkers, including trajectory of clinical response, to predict clearance and remission duration to UVB phototherapy

J Eur Acad Dermatol Venereol

Watson N, Wilson N, Shmarov F, Zuliani P, Reynolds NJ, Weatherhead SC

doi: 10.1111/jdv.17519

Psoriasis

Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3

J Eur Acad Dermatol Venereol.

Warren RB, Hansen JB, Reich K, Paul C, Puig L

doi: 10.1111/jdv.16816.

Psoriasis

Alcohol abuse associated with poor response to systemic therapies for psoriasis: findings from a prospective multicentre cohort study

Br J Dermatol

Iskandar IYK, Lunt M, Thorneloe RJ, Cordingley L, Griffiths CEM, Ashcroft DM, British Association of Dermatologists Biologics, Immunomodulators Register, Psoriasis Stratification to Optimise Relevant Therapy Study Groups.

doi: 10.1111/bjd.20577

T Cells

A skewed pool of resident T cells triggers psoriasis-associated tissue responses in never-lesional psoriasis skin

J Allergy Clin Immunol.

Gallais Sérézal I, Hoffer E, Ignatov B, Martini E, Zitti B, Ehrström M, Eidsmo L

doi: 10.1016/j.jaci.

Related content

Response to ustekinumab treatment in patients with systemic lupus erythematosus is linked to suppression of serum interferon gamma levels

Serum CRP, IL-17A, and IL-17F levels are responsive to ustekinumab in psoriatic arthritis: lessons from the PSUMMIT study programme

Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study

Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis

Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus

The use of psoriasis biomarkers, including trajectory of clinical response, to predict clearance and remission duration to UVB phototherapy

Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3

Alcohol abuse associated with poor response to systemic therapies for psoriasis: findings from a prospective multicentre cohort study

A skewed pool of resident T cells triggers psoriasis-associated tissue responses in never-lesional psoriasis skin